Abstract
Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who was successfully managed by switching to brigatinib, another ALK inhibitor. The patient achieved excellent anti-tumor response to brigatinib. Our case provides an alternative and safe strategy in patients with alectinib-related hypersensitivity.
Original language | English (US) |
---|---|
Pages (from-to) | 73-77 |
Number of pages | 5 |
Journal | Lung Cancer: Targets and Therapy |
Volume | 9 |
DOIs | |
State | Published - 2018 |
Keywords
- Alectinib
- Brigatinib
ASJC Scopus subject areas
- Oncology